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Over the last decade increases in the understanding of human
carcinogenesis have been remarkable. While this knoss ledge is far
from complete. the identification of specific genetic and molecular
events promises to radicallx alter the ax cancers are treated bx
elucidating molecular targets br new pharmaceutical agents. A t’es
such drugs ha\ e already been developed including Gleevec. target—
ng c-kit; lressa. targetin epidermal grms th tactor receptor: and
Herceptin, targeting the HER-2!neu (HER-2) protein. These agents
show promise as primary treatment or as adjuvant therapy combined
with standard treatments such as surgery. radiation therapy. chemo—
therapy and hormonal therapy. This new experience with
“pharmacogent liii ic” has aI so brong hi new challenges t’or the
diagnostic lah )ratory ihe proper iden ii heat ion of pale ills who max
benefit from these new drugs is critical. Equallx important is
identify ing s ho is not a good candidate as these drugs may have
serious side et’h.cts and are \ cry expensive. This new developing
pathology practice of identifying and characterizing therapeutic
targets has been termed “pharmaeopathology”. The current contro
versx surrounding the laboratory evaluation of HER-2 status is the
pri me example ol this ness dilemma in diagnostic pathologx It is
orthwhile for pathologists and clinicians alike to examine this
debate br it is a preview of hat may well follow as more molecular
based therapies advance throtigh the clinical trial phase and into
clinical practice. The I—IER-2 debate is an object lesson in why close
interaction bets ccii the clinician and the pathologist is becoming
more and more important. It is imperative that the pathologist
becomes more familiar with the management implications of diac
none tests. Likess ise. clirucians must realite that there is more to
patho logic es al tian m than a hard cops result. Proper i nterpi’etat ion
of pathologic i’eults. sshether they be front your local lab or data
appearing in the peer-revtesvel literature, require-s an understanding
of ilie testing process. The HER—2 storx is a complex one that
ins olves not only lahoratorx practice hut also significant marketing
and economical concerns. ‘1 hese “non-medical” forces must he
understood as they clearly affect what appears in the peer-reviewed
literature on this ‘uhject and directly shape marketing campaigns to
hnieians and patholovists. In this eomnientarv I seth attempt to
summarize the in[ormaiioii. and misinf’rination. currently avail-
able and proPose a rattonal approach to HFR—2 tesinic.
The current lehaie foe u se ‘n svhat Is the pre ferret I met hod t) r
HER -2 evaluati n. While several methods have been emploed
since the discovery of the HER-2 gene and protein in I 9y5, the two
Jinie ills i dr s tnt methods u immunohistochamistis (IHC md
fluorescence in situ lix hriditation FISH). IHC is used to measure
receptor protein expression and F ISH is used to meastire HER-2
gene copx number. ‘I’he controversx centers around the reliability of’
IHC-hased HER-2 testing and ss hether FISH should be the testing
method of choice. To sort otit this conundrum it is best to first res iew
a few aspects of HER-2 hiolog . the laboratory issues in the
development of anti—I IER—2 therapy and the processes of immuno—
histochemistry and fluorescence in situ hybridization.
Overe\pression of the HER -2/tic n gene can be demonstrated in
2t)-30 ot invasive hi-east cancers,’- The gene is located on chi’omo
sonic I 7q and encodes a transmeinbrane tvi’osine kinase receptor
related to epidernial growth t’actor. In most, but not all. cases
overexpression of the HER—2 protein (called p1 5) is associated
with amplification of the I-{ER-2 gene. The importance of HER-2
alterations is two-fold in that it has both prognostic and predictive
value, Prognostically. tumors with overexpression or amplification
are associated with shorter disease-tree and os erall survival ss hile
retrospectis e sttidies has e shots n that HER—2 alteration mae he
predictit e of response to certain tx pes of chemotherapy: \Iost
iinportantlx. the H ER—2 protein is the target of’ trastu,umah
I Hereeptin ). the humanized monoclonal antibodx now available for
the treatment of breast cancer. Optimal use of this drug requires
accurate determination of HER-2 status.
In 1993. as a result of clinical data from the Hei’ceptin trial. it was
apparent that a commercially as ailable IHC test was necessarx to
determine patient selection for Herceptin. At that time, practical
gene—based tests ssere not available. [)uring the trial a combination
oh two antibodies called the “Clinical Trials .-\ssax I CTA j” had been
used to detect overexpression. The IHC stainmo seas Semi-quantita
tively assessed on a 4-tiered scale 0. 1+. 2+.3+) by evaluating the
amount and intensity of cell membrane staining. Pre-clinical work
suggested that Herceptin activity required a receptor density greater
than 100.000 to 200.001) per cell. i’his roughly corresponded to an
I BC score ofat least 2+ bx CTA so patients ss ith 2+ or 3+ scores were
considered candidates for Herceptin while those ss ith scores ofO or
l ± s-vere considered non-overexpressed. The (‘TA assay was costly
and h ft’ictilt to perform making it an I mpracti cal test corn mercial lv.
Genentech. the makers of Herceplin. granted Dako Corporation a
license to develop an IHC kit that could he commercially used to
detect HER-2 overexpression. The original tumor samples from the
patients in the Herceptin trial had deteriorated so the newly devel—
oped antibodx and testing protocol HercepTesi t along with the
(‘TA wei’e applied to a lai’ge set oftumors obtained from the \atinal
Cancer Institute. The tumor set was specificallx cho’en to have
equal niinihers of positi e 12+. 3-i-i and negatE e 0. I
--t case’S. This
is a far rn re rigorotis scenario than actual eluueal practice ss here
approximately $0%- of eases will he clearly normal (C. 1±) or clearly
overexpressed (3+). The comparison study- showed a concordance
between CTA and He i’eepTest of 79ff. Based on this, the FDA
unanirnouslx appros ed I-IercepTest as the method for determining
pattent eligihilits for I Icreeptin. The I IereepTei procedure is more
than just the polx elonal autibodx clone A04S5 , In an attempt to
minimize ,triation from lab to lab the kit also includes all reagents
along ‘nIh a speeitie te’ting protocol and detailed intei-prenve guide.
Because most of the criticism of the IKC method of HER2
assessment is centered around the reported variability of the JHC
method i hi tel rex mss of the lH( process is 1+ eLi-S mr Th fH(
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uiethod tor ideniit\ me 1 cilic timleins in istoliui,iic prepm’atious
has been common in the pathology laboratory for over A) sears and
is performed daily in most labs. The method consists ol multiple
steps. all of which can he moditied by the laboratory to optimize the
desired result. These processes include tissue tisation. antigen
enhancement techniques. incubauon tunes and conditions. dilution
ot’the primai’ antibodies and detection methods linking niolecules
and c hioniogcns . In essentiails all antibodies routineis used hs
pathologists the primary goal is to determine it a certain protein i5
present or not. For example. IHC stains for keratin may he used to
determine if a tumor displays evidence of epithehal origin. The
pathologist does tot care hoi infO/I keratin is presenL tu’t 55 herher
it is there or not. Because 01 this “yea or nay” approach procedures
for specific IHC stains ai [rom lab to lab, dependine on lab
preference Antibodies themselves \ ar in that ditterent “clones’
are available which may detect similar, but not idemical. epitopes.
No less than seven antibodies directed against various epitopes of
the FTER-2 protein are commercially a ailable: It is not surprising
that inlerlahorat&irx variabilitx es nIt’ in this setting but ss ith “quali—
talis e’ Il—IC this Is not a mator problem. The IHC deternunation ot
HER-A howes em. is unlike any other IHC test. Because HER- s
also present on normal breast epithelial cells it is necessary to
quantitate the number of receptors present and establish a cut-off
point above which “over-expression” is present. This concept of
“quantitative IHC is ness for pathologists. While the Hercepiest kit
introdticed the concept of quantitati\ e I HC. it ss as also am more
expensive for laboratories to utilize compared to other HER
antibodies. As a result. mans laboratories altered the pr cednres.
both in testing conditions and in the antibodies used, Manu of these
deviations formed the basis of HER—2 results reported in the litera
ture and it is not surprising that variation resulted.
With this background on the des elopment and variation in the
laboratory methods of IHC’ ss e can h ok at the criticisms of this
method ofi IER—2 assessment A major [actor adding to the intenslt\
of the discussion was the availability of an alternatis e testing
method, fluorescence in situ hybridization (FISHL Becaise of the
stability of DNA, FISH testing could he performed on tumor
samples previonsl\ tested h\ Il—IC and the results compared. In spite
of ss hat is implied in FISI I inarkctiue tactics, the procedure i not
simple. It includes its own set of variables including tissue fixation.
testing conditions, probe charactemtstcs and Interpretive cmterma. In
addition, FISH is significaitl\ mome e\pensivc and perlomnmed by tam
fewer labs than IHC, This latter point is the primary reason that
variahi litv studies done to date hase suggested FISH is more
reproducible than IHC. As FISH testing becomes more ss despread.
interlabomator\ ambition ill become mome otj prnhteui \\ hen
IH( F NH omp iis t di,s i mc s ii q m o
regarding the accu racy of IFIC. and h ninijeation. he eli,hdjiv
patleill selection iou Flereeptin therapy. This ietter issue, that of
patient fe...lection, .s espe.ciail.v important for Ge.nentech, the mnanu.
facturem ofHe.rceptin. If the test used to sri.e.ctthe patients mist li.kely
to resp mcI is tlao ed the perceived ci fisacv 01 the drug is II risk. A
a result. Gcncntcc[i has bee aetise i the ue-’iiiuine the [FIC
method ,msi ha been tioiii’tine FISH nethodi.igr.
The utost coninonl cited slud\ 0\ tii’iC fiSiS occall 1-loll ci
i.FIC fom HER.-2. testing L•s the report by Paul.etti et al In hat. study
900 c iscs ol ins lsl\c htc ist mcci di ignosed Oct Scch I 9y7 md
1091 in South Australia sere tested for IIER—? status h\ IHC and
FISH ss ith results comnpared ss ith patient survis al. Both methods
were independent predictors of survixal on multivariant analysis,
By unis ariate analysis, there was a direct correlation between
survival and gene eop\ number determined hs’ FIS I-I while that same
relationship sa5 OuI\ seen in the strongest stai lug IHC emoup 3+-i.
I’li i stnd\ has bee ii put I ri Ii as cv idenec’ that F 1511 is t lie more
test. Keepine in mind the intricacies of !HC neIhodtlng\
discussed earlier, ii is worthss file taking a closer look at the I’auletti
study, This re—analysis was well described by Yaziji and Gown and
a lCw pertinent findings stated hete,! The authors of the 1-Liuletti
studs used the Rho polycisial ntihds ss hieh is nit svidcl\ avail
able amid has been intiequcit]s studied. They did not use antigen
m’eti’ies-al ss hich is considered standard in most Lbs todas - They
utilized the pem’oxidase-antipc’m widase Ictectiomi system Imich ss as
comiTlon in the SO’s and early 90’s hut lias since been meplaced by
more sensitive methods such as avidin-hiotin or streptavidin-hiotin.
These technical problems ss tb the Pauletti studs likely- introduced
both false psitve ti1cl false ley’atis e IHC mcsult leading to the
suboptunal performance 1 their INC asa5. Another studs maismn
concerns about t[me IHC method is the \atioiial Surgical -\dinvant
F3reast and Bowel Project (N SABP t Pm’otocol B-3 I ss hich looked at
the benefit of adding Herceptin to chemotherapy. ‘ Eligibility was
based on HER—? results from the accruing institutions and included
eases that svere either 3+ by HercepTest. showed strong membrane
staining ml other HER-? antibodies were used. sir gene amplitmcaton
by FISI-l. (‘entral I IER—? retesting WUs pert orned for the I must I (K
case’s entered and showed that l tO-s of the comiuunts -based assays
could not he confirirted by- central HcmcepTest or FISH assay. The
authors questioned the reliability of IHC performed in lower volume
laboratories since repeat IHC and FISH testing at the central, large
volume sib showed corcordance 94 of cases.
A third example ot problems witlt I[IC can be found in the
experience of tile Bi’east Iutergm’oup Trial \OSci I ss-hicim also is
csaluiing llemeeptin in the sidus ant settimig.,-\ secondars endpoint
of the trial is to assess concomdance hetss een Hem’cenTest and FISH
at a central testing facility. Eligibility was the same as the NSABP
B-3 I trial. Of the first 119 patients entered. 110 had local IHC testing
NP’ sal’ tine [nd loch F1S1-l ,issas s. On central Il--IC repeat testing
nE Si oithe 110 E3ks shosscd 3± staining with Hei’eepTest. Tlis
agaIn raised s,i”’ concerns shot it the accuracs of IHC. pam’ticu
any ss hen perlonued In 055cr volume communts laboratories,
What is not emphasized by those who cite this.-.- study as evidence of
FIKFI superiorit-.v is that local vs.-. c-entral Fi.SH assays als.:o showed
poor c oneordancc. 0-f the nine u.tients entered with local FISH.
eenc cal iitc,iissn. ouTs ix acre- culsrimcd
n c’entissl FISH testing Whets hth IF-It and FISH ss-ere pet irmed
hr tie central an t’’ a-is 0? c-icrdanc’e - e C disc m’dnce
eonsisted of cases that. we-re 3+ by He-recpTe-st but norm-ampi i Led by
[S-[5fj a cons-istent subgroup that will be. mentioned later.
‘the pobhcation ssf these stodies and some- others led to q-oestton
Inc n-f tTtc reliabhhs— cs-f INC for detc’rssiiing HER--? s tams. This
eli II R::’ rv—s’n supp’ttscd h’ (ienentcels cad th’.e , nh ntere!s in
FISH iechnssshgs - 5:hgcgs:ly gn’, nnhihc-d ep’rts Misc tot-
iFiC s tact. scry elieble whoa tri-ct
adherence to te-sting and inn --preti\-’e- po-ooe-oio- sire toilow ccl. it
h t’ Iso Oven vIe ii son1 tin c tI g tI Th II N ityLot’ should
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not he coitsidered o c’-exprcsscd” and requires additional tcstme.
In spite of this fact, the proponents of FISH continue to cite studies
that included 2± reactions as “positive” as evidence of the shortc oni
ings ol INC An example 01 the excellent results that can he ohtained
o hen high qualits IHC isperfonned can he seen in the data pi’csented
hs Yaxiji ;md Goo ii. Atnone the 3 I tumors nceaiivc for mipIih
cation hs FISH, ouR ix I It’’ showed 2± staintnc on INC. Nt the
cases postliSe toroerc\pre’ion on IIIC P-t’ ucrc atnplihcd
hy FISH. This and many other studies pnhlished in the last 3-5 cars
as well as data from our own lab confirms that I HC, when well
pertornicd is highlr accurate in determining HFR-1 status.
As ou can sec run this dicus5ion the farce najorit\ of the
literature addressuig the issue a 11—IC I-dSH tor HER—2 tesimig
consists cfcmtparisitn studtes and retrospective slLii lies limkina at
HER-2 as a prognostic factur As ntentii’ned prc\ iousfr, inatir of
these studies are seriously flawed h variation in INC testing
practice and inconsistency in how results arc reported. What has
been lacking until recently is data shou ing the direct relationship
hetwecn HER—2 testinc methods and patient response to Herccptn.
This important data is itow stalling to appear in the literature. Ir data
suhmitied to the FDA from the Hcrccptn Clinical Trial I H(ib1Sc
significant impros enient in time te prouress ion o as seen in patients
receiving Heceptin plus chemotherapy compared v ith those receiv
ing chemotherapy alone, This henelit was not only seen in patients
o howerc I HC 3±/FISH± hut also in a suheronpof patients ss ho \s crc
I H( FISH in,, ii lst iii it FISI Ii 1 1 In tuds
evaluating Herceptin as a siitule first-line agent in patients with
netastatie hieast cancer. 29 paticnt ohio crc IHC 3 responded to
Herceptiti. Twentr —‘even patients with FISH positive tumors re
sponded however 2 patients who were FISH negative (7N ) also
showed ohiective t’e sponse. Most recentlr . in a phase H monothcrapy
trial from Germanr. clintcal i’csponse to Flerceptui o as limited to
those patients with I HC 3± tutnois. Most of these o crc also FISH
pOsitlse hut tlree patients \ It’ responded store FISH negatis e. a
FISH false nceati\ c rate of 5’. Clearly, the most recent and
clinically relevant data shoo s that a strongly positive lH(’ test
correlates hest with patient response. This only makes sense given
that the target of Herceptin is the p185 nrface protein, the protein
in i tt’ I tis IH( In tnt itt I t is I NH shot Id b
ttiokeu at as a “surrocate” tcst tor Herceptin elicihility, It appears
there is a snia]t, 7—I 5’7 hut eensstent_ v’ri’ttpe’ patients ho are
1 HC±FIS H that e ill respond to Herceptin. This may he due to
c.hromos.ime 17 polysomy or low-le.ve 1 n pl.ificat.ion with FISH
HER.—2. rarios he.twcen I .f) and 2,fl.
It seems the.n that \daen we I okfor the’eptimal tc.sting method for
HF_R—2 i,itus ‘nsc’ ba’.ee’u’ac baIi etude. Wei5ccatt o. tth IHC tad now
it t cieat that Il—IC. indeed. i’ the hest -line tct What 55 e
d u I . i t i iii ,
critical than t.he met [a td it.sc’ I C. A laboratory that. I..ci1ort.sn.: 1 HC i.n a
slopp I stitot vs ill ItkJs put it a F NH Jrtst s po tt H If t I hi ir i
tory c.a.nnu ensure tha.t t.fe. appropriate procedures are followed a.nd.
that HER•-2 rest.tlts are continnuils l.Onit’ .rc(l a.tld ci ate analysed then
s.ifniCs ‘5’,i’LIlci 1’d r’tei’tdJ to tIlel haSC th’.e pisseedures in
I ( 5 1 —
a HE.R-2 qualbc control pr’::uratn to hel’ labs ec.tciress tilts
While. FISH. is an elte.rnati.ve to IHC in [irst.-li.nc testjtlss, a more
ippropt t tr Ic s tt cont tt mit g ho CC1tltle or 2± 11-IC e oc It ts
,ippi oech utili/in’ II IC a’ the nutiat test [‘olloo ed hr retlex FISH
testin’ br nd k. mutate cases ha noo been support ‘ci hs niatis
oup and is uI I id di thc i cent N ition’ul C omp It tlsise C inc r
‘sL tor k INC C N) fiuid im
In otur lahoi utors or has e optimiied the interpietatton of
1-Icr cep lest hs tpplr inc di ital i iniputertied tniaec ,mals sis. l’he
N ttnage atiak si’ ‘r stCtiu t C’hronia\ isittil \ledicai 85 sterns. San
in in C ipusnri’ C \ utiluzescusti’tn sotto arc ti tyils /c H ‘reepi cst
I I IC t tins 1 his t hit iqct is more t cu ute th tn i lanual s ‘o ing and
itupto s rr ut, i ii t - \i to 11’ t ci IHC an’ds SN oil! lik H
hecotn t iot ‘0 fl0tl, th ‘ate,i of ph tuner opcitholoi parids
Il ,,ot Itisti ‘it. rh, s,tC,t if HF H 2 nu’ tetin” is Ci impie\ htit necs
‘air to rind i’standtoi it ts,is tion itt the tLttLnc ssheie multidisciplinarr
inter a lion. ertt’c,’l liter ttmc res co and hit cit healthr skepticism
ttc tt ded tori t ‘rnune tlt path to optimal pati ‘itt cue. \\ hilt.’ I IF.R
I tttl s ill on t flue to ols e ‘urrcn dat indicates the opttm’ I
te til’ t atu h uld cmplos qt dtts IHC o ith eli ‘x FISH tcstint
tit in I a i tttmat esults,
F ‘i iritot tt,itii,i ott the C aiker Rescaich C entet ol Nassau, please
‘i’it oo o .ci’ch.oi
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